Share on StockTwits

Equities researchers at Credit Suisse hoisted their target price on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $340.00 to $400.00 in a research report issued on Tuesday. The firm currently has an “outperform” rating on the stock. Credit Suisse’s target price would suggest a potential upside of 14.14% from the stock’s previous close.

A number of other analysts have also recently weighed in on REGN. Analysts at Leerink Swann raised their price target on shares of Regeneron Pharmaceuticals from $389.00 to $436.00 in a research note on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to an “underperform” rating in a research note on Tuesday, August 26th. They now have a $316.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $352.11.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 350.455 on Tuesday. Regeneron Pharmaceuticals has a 52-week low of $245.99 and a 52-week high of $354.79. The stock’s 50-day moving average is $328.2 and its 200-day moving average is $312.7. The company has a market cap of $35.182 billion and a P/E ratio of 98.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.15 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $350.31, for a total value of $700,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.